Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2013

Westblade LF, Jennemann R, Branda JA, Bythrow M, Ferraro MJ, Garner OB, et al. Multicenter study evaluating the Vitek MS system for identification of medically important yeasts. J Clin Microbiol. 2013;51(7):2267-72.

Varma S, Scognamiglio T, Hoda SA. Beasts in breasts. Int J Surg Pathol. 2013;21(4):373.

Mosquera JM, Sboner A, Zhang L, Kitabayashi N, Chen C-, Sung YS, et al. Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosomes Cancer. 2013;52(6):538-50.

Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, et al. PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Res Treat. 2013;138(2):369-81.

Zou W, Greenblatt MB, Brady N, Lotinun S, Zhai B, de Rivera H, et al. The microtubule-associated protein DCAMKL1 regulates osteoblast function via repression of Runx2. J Exp Med. 2013;210(9):1793-806.

Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, et al. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet. 2013;45(7):747-55.

Heymann JJ, Saqi A, Turk AT, Crapanzano J. Micropapillary urothelial carcinoma: Cytologic features in a retrospective series of urine specimens. Cytojournal. 2013;10:4.

Tabbo F, Ponzoni M, Rabadan R, Bertoni F, Inghirami G. Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma. Curr Opin Hematol. 2013;20(4):374-81.

Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol. 2013;63(5):920-6.

Martz J, Jain S, Vahdat LT, Qin L, Mosquera JM, Antonescu CR, et al. High-grade KIT-negative sarcoma of the small bowel in a patient with chronic myeloid leukemia receiving long-term tyrosine kinase inhibitors. J Clin Oncol. 2013;31(11):e181-5.